The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC/IF: 1/250 - 1/500.
WB: 1/10000. Detects a band of approximately 37 kDa (predicted molecular weight: 34 kDa).
Is unsuitable for Flow Cyt or IHC.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionThe Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.
Sequence similaritiesBelongs to the CRK family. Contains 1 SH2 domain. Contains 2 SH3 domains.
DomainThe C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation. The SH2 domain mediates interaction with SHB.
Post-translational modificationsPhosphorylation of Crk-II (40 kDa) gives rise to a 42 kDa form. Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the down-regulation of the Crk signaling pathway.
Cellular localizationCytoplasm. Cell membrane. Translocated to the plasma membrane upon cell adhesion.
Immunofluorescent staining of HeLa cells using ab45136 at a 1/250 dilution.
References for Anti-Crk p38 antibody [EP242Y] (ab45136)
This product has been referenced in:
Ahn J et al. The metastasis gene NEDD9 product acts through integrin ß3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci125:1814-26 (2012).
Read more (PubMed: 22328516) »